First Tracks Biotherapeutics, Inc. (TRAX)
About First Tracks Biotherapeutics, Inc.
First Tracks Biotherapeutics Inc is a clinical-stage biotechnology company focused on delivering immunology therapeutics for autoimmune and inflammatory diseases. Its clinical-stage pipeline includes rosnilimab, a selective pathogenic T cell depleter, for which it completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA), ANB033, a CD122 antagonist, in a Phase 1b trial for celiac disease (CeD) and eosinophilic esophagitis (EoE), and ANB101, a BDCA2 modulator, in a Phase 1a trial. The company operates in one reportable segment focused on research and development activities to deliver immunology therapeutics for autoimmune and inflammatory diseases.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Net income
- -$50.5M
- Total assets
- $290.6M
- Market cap
- $579.2M
Source: SEC EDGAR · updated Jun 7, 2026
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $579.2M
- Shares outstanding
- 16.3M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Apr 6, 2026
First Tracks Biotherapeutics, Inc. (TRAX) Stock Price
- Reported a net loss of $50.5M.
- Trading 7% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review First Tracks Biotherapeutics, Inc..
Write a review
First Tracks Biotherapeutics, Inc.: frequently asked questions
Is First Tracks Biotherapeutics, Inc. an American company?
First Tracks Biotherapeutics, Inc. is a US-based company headquartered in San Diego, California, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Where is First Tracks Biotherapeutics, Inc. headquartered?
First Tracks Biotherapeutics, Inc. is headquartered in San Diego, California, United States.
Is First Tracks Biotherapeutics, Inc. publicly traded?
Yes — First Tracks Biotherapeutics, Inc. is a publicly traded company. Its stock trades under the ticker symbol TRAX on the NASDAQ.
What does First Tracks Biotherapeutics, Inc. do?
First Tracks Biotherapeutics, Inc. is an American Pharmaceuticals company in the Health & Beauty sector.
